Competitive Pressures Mount with FDA Biosimilar Approvals

The biotechnology giant Amgen finds itself navigating a complex landscape where groundbreaking innovation collides with mounting competitive pressures. While the company faces imminent challenges from newly approved biosimilar drugs targeting its key products, it simultaneously advances a promising pipeline of novel therapies that could redefine its future growth trajectory.

Significant headwinds have emerged for Amgen following the U.S. Food and Drug Administration’s approval of BILDYOS® and BILPREVDA®, Read more...